Who
Christi Shaw
Director
Company insider
Files Form 4 as: Director, Beam Therapeutics; Executive Chairperson, Kyverna Therapeutics; Director, Avantor; SVP and Pres., Lilly Bio-Meds, Eli Lilly and.
In numbers
- Trades disclosed
- 36
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $3.5M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 1 May 2017
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —19,676 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —19,676 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code F | $36K4,194 at $8.59 | filing |
| 27 May 2026filed 29 May 2026 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code F | $36K4,194 at $8.59 | filing |
| 12 Jan 2026filed 14 Jan 2026 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code A | —24,301 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code A | —24,301 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —33,662 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,351 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,634 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,679 at $0.00 | filing |
| 16 Sep 2024filed 18 Sep 2024 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,592 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —23,114 at $0.00 | filing |
| 13 Dec 2023filed 14 Dec 2023 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —39,046 at $0.00 | filing |
| 11 May 2023filed 15 May 2023 | AVTR AvantorLife-science tools | SEC FORM 4 Code A | —9,808 at $0.00 | filing |
| 12 May 2022filed 16 May 2022 | AVTR AvantorLife-science tools | SEC FORM 4 Code A | —6,693 at $0.00 | filing |
| 1 Apr 2022filed 5 Apr 2022 | AVTR AvantorLife-science tools | SEC FORM 4 Code A | —1,215 at $0.00 | filing |
News
Here's What I'm Planning With My Eli Lilly PositionLLY · fool.com · 21 Oct 2026Eli Lilly, Mubadala Bio Plan Abu Dhabi Packaging for GLP-1 MedicinesLLY · econotimes.com · 21 Oct 2026Stock Market Midday, Oct. 20: Blue Chips Rally, Eli Lilly Gains 5%LLY · fool.com · 20 Oct 2026
0 headlines in the last 90 days name Christi Shaw; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.